Angiotech Pharmaceuticals (ANP.TO) Buy, Sell…

Angiotech Pharmaceuticals (ANP.TO)

0.00

-0.00 (0.00%)

2 watching

DON'T BUY

A great company but not something you should get into at this point. Can't see much upside in the near to intermediate term. Having real problems with clots on their stents. Losing market share. Guidance going forward is coming down. Sold her holdings.

DON'T BUY

Have been a lot of concerns on their stent products. As a result of this, they acquired a company that would give them revenue and earnings in the event the stents were pulled. Still a lot of risks.

PAST TOP PICK

(A Top Pick Oct 16/06. Up 9.1%.) Still comfortable with this one. Decent, longer-term story.

BUY

Got hit with the stent recall for Boston scientific. There are some long-term issues with stents. FDA has decided that the safety issues were not enough to outweigh the benefits. Most of their earnings in the next couple of years will be coming from new products in the pipeline, not stents. Have been very active in acquisitions.

WAIT

Have been trying to diversify away from their stent business, which is their major source of revenue. There is a fair amount of competition in the sector. Because of the drop in the share price, it could be subject to some tax loss selling.

TOP PICK

Stock has come down a long way and valuation looks good. Maintaining their share of the coated stent market. That alone could justify the current price. Acquired another company where they can use the coated technology on other products. Lots of cash. Trading at 12 X earnings.

PAST TOP PICK

(A Top Pick Aug 21/06. Down 19%.) Had some issues with Boston Scientific (BSX-N) and some problems with their stents. Royalty rate is going down. Still likes the company. They are relying less and less on stents.

DON'T BUY

Has been under pressure because of competition on their stents. Some controversy as to whether the coated is better or not. Because of this, it is more of a speculation than an investment.

TOP PICK

Has been pummelled in the past year. A bit of a contrarian play. Trading around 11 X forward earnings. Made in acquisition that has a great pipeline and, basically, you are paying nothing for that. The stent market is still growing.

BUY

Management is great. It is trading at a low price. Believes it is a buy.

TOP PICK

Stock recently hit a 52 week low. He is looking at the turnaround here. It has some growth and a good balance sheet. It is in a sector that he likes.

BUY

Has come under a bit of pressure which now seems to be easing. Their main business is drug coated stents which they get royalties on. Recently made an acquisition and some of the synergies are now going to start working their way through.

TOP PICK

Tainted with the stent problem in the US. Incredibly attractive from an earnings point of view. Did some acquisitions that give them 200 new products that they will coat with the same technology they used for their stents.

PAST TOP PICK

(A Top Pick July 4/05. Down 27%.) Below the 50/200-day moving averages. Chart shows a strong downtrend. Had suggested this as a Christmas rally stock.

TOP PICK

Just made a major acquisition. Their coated stent product is still going well. The stock has come under a lot of pressure. They are generating cash and trading at 12 X earnings.

Showing 16 to 30 of 140 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Angiotech Pharmaceuticals (ANP.TO)